The immunological aspects of latency in tuberculosis

被引:126
作者
Chan, J
Flynn, J
机构
[1] Yeshiva Univ Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA
[2] Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA
[3] Univ Pittsburgh, Sch Med, Dept Mol Genet, Pittsburgh, PA 15261 USA
[4] Univ Pittsburgh, Sch Med, Dept Biochem, Pittsburgh, PA 15261 USA
关键词
Mycobacterium tuberculosis; infection; immune response;
D O I
10.1016/S1521-6616(03)00210-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
A unique feature of Mycobacterium tuberculosis is its ability to exist in the granuloma of an asymptomatic host in a latent state that can subsequently reactivate to cause active disease. The latent state of infection poses a major obstacle to eradicating tuberculosis. In latent tuberculosis, the host immune response is capable of controlling the infection and yet falls short of eradicating the pathogen. That the host immune response contributes to the maintenance of latent tuberculous infection is supported by the observation that certain immunodeficient states, including those associated with the human immunodeficiency virus and tumor necrosis factor neutralization therapy, are associated with increased risks for developing reactivation disease. Latent tuberculosis is the product of a complex set of interactions between M. tuberculosis and the host immune response. The molecular basis for the persistence phenotype of M. tuberculosis and the pertinent host immune mechanisms that contribute to the maintenance of tuberculous latency are just beginning to be understood. This review discusses the interactions between M. tuberculosis and the macrophage, the primary host cell that the tubercle bacillus parasitizes. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:2 / 12
页数:11
相关论文
共 129 条
[1]  
ADAMS DO, 1976, AM J PATHOL, V84, P164
[2]   EXACERBATION OF ACUTE AND CHRONIC MURINE TUBERCULOSIS BY ADMINISTRATION OF A TUMOR-NECROSIS-FACTOR RECEPTOR-EXPRESSING ADENOVIRUS [J].
ADAMS, LB ;
MASON, CM ;
KOLLS, JK ;
SCOLLARD, D ;
KRAHENBUHL, JL ;
NELSON, S .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (02) :400-405
[3]   Infliximab downregulates interferon-γ production in activated gut T-lymphocytes from patients with Crohn's disease [J].
Agnholt, J ;
Kaltoft, K .
CYTOKINE, 2001, 15 (04) :212-222
[4]   RESPONSE OF CULTURED MACROPHAGES TO MYCOBACTERIUM-TUBERCULOSIS, WITH OBSERVATIONS ON FUSION OF LYSOSOMES WITH PHAGOSOMES [J].
ARMSTRONG, JA ;
HART, PD .
JOURNAL OF EXPERIMENTAL MEDICINE, 1971, 134 (03) :713-+
[5]   THE DISCOVERY OF LYSOSOMES [J].
BAINTON, DF .
JOURNAL OF CELL BIOLOGY, 1981, 91 (03) :S66-S76
[6]   PATHOGENESIS OF TUBERCULOSIS - PATHWAY TO APICAL LOCALIZATION [J].
BALASUBRAMANIAN, V ;
WIEGESHAUS, EH ;
TAYLOR, BT ;
SMITH, DW .
TUBERCLE AND LUNG DISEASE, 1994, 75 (03) :168-178
[7]  
Bean AGD, 1999, J IMMUNOL, V162, P3504
[8]  
Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424
[9]   Immunopathologic effects of tumor necrosis factor alpha in murine mycobacterial infection are dose dependent [J].
Bekker, LG ;
Moreira, AL ;
Bergtold, A ;
Freeman, S ;
Ryffel, B ;
Kaplan, G .
INFECTION AND IMMUNITY, 2000, 68 (12) :6954-6961
[10]   TUBERCULOSIS - COMMENTARY ON A REEMERGENT KILLER [J].
BLOOM, BR ;
MURRAY, CJL .
SCIENCE, 1992, 257 (5073) :1055-1064